The court victory again Novartis in India is essential for cheaper drugs available in developing countries.
- Generic Competition Pushing Down HIV Drug Prices, But Patents Keep Newer Drugs Unaffordable (medicalnewstoday.com)
- Patents keep newer HIV drugs too pricy for developing countries, Doctors Without Borders says (vancouverdesi.com)
- WHO: Treat people with HIV early to stop spread (arkansasonline.com)
In the mid-1990s in sub-Saharan Africa, HIV and AIDS were decimating the populace. Families, communities and workplaces were torn apart by these crippling and debilitating conditions and there didn’t seem to be any end in sight. At that time, HIV medicine cost a staggering $10,000 per person per year. And that world just seemed to accept that many people were priced out of treatment and there was nothing that could be done about that.
But that wasn’t the prevailing opinion for everyone and so changes were made. In fact, what really made the biggest different was the availability of quality, affordable, generic medicines that were being produced in India. There was a lot of competition between the producers and hardly anyone in India with the condition, and as such, the price dropped enormously. Today it costs around $100 for a year’s treatment.
For the large organisation Médecins Sans Frontières, around…
View original post 124 more words